The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s…
